Orum Therapeutics, Inc.
KKRX:47583016,940.00
KRW
-260.00
(-1.51%)
ISIN
KR7475830006
Return %
Stock
S&P 500
1Y
-52.15
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seung-Ju Lee
- Full Time Employees
- 21
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 281-25 Munji-ro Daejeon DE South Korea 34050
- IPO Date
- Feb 14, 2025
- Website
- orumrx.com
- Similar Companies
- Business
- Orum Therapeutics, Inc. (KRX: 475830) is a clinical-stage biopharmaceutical company that develops novel targeted protein degradation therapeutics, including degrader-antibody conjugates (DACs) and dual-precision targeted protein degradation (TPD²) technologies combining the precision of antibodies with protein degrader payloads to selectively degrade intracellular targets in cancer cells and other diseased tissues. The company offers a pipeline of product candidates such as ORM-5029 for breast cancer; ORM-6151, a first-in-class anti-CD33 GSPT1 degrader initially for acute myeloid leukemia and other CD33-expressing malignancies; ORM-1023 for small cell lung cancer and neuroendocrine tumors; ORM-1153, a GSPT1 degrader targeting hematologic malignancies; dual-precision targeted protein stabilization PROTAb; and casitas B lymphoma-b platforms, alongside proprietary linker technologies and GSPT1 degrader payloads for antibody delivery to enhance therapeutic index, bioavailability, selectivity, and safety against previously undruggable targets in oncology and immune diseases. Founded in 2016 and headquartered in Daejeon, South Korea, with additional operations in Lexington, Massachusetts, USA, Orum Therapeutics targets global markets in biotechnology research, focusing on customers worldwide including pharmaceutical partners for cancer therapies and gene editing applications. Recent major developments include the November 2023 acquisition of its ORM-6151 program by Bristol Myers Squibb for an upfront payment of $100 million plus milestones totaling $180 million, now advanced as BMS-986497; a July 2024 multi-target license and option agreement with Vertex Pharmaceuticals valued at up to $310 million per target for up to three targets, enabling development of novel targeted conditioning agents using TPD² technology for gene editing; a 2025 debut on the Korea Exchange's KOSDAQ market raising approximately $34.7 million; and preclinical data presentations for ORM-1153 at the 2025 American Society of Hematology Annual Meeting.